PUBLISHER: BCC Research | PRODUCT CODE: 1110044
PUBLISHER: BCC Research | PRODUCT CODE: 1110044
The global market for human reproductive technologies and products is valued at $16.1 billion in 2021 and is estimated to grow from $17.1 billion in 2022 to $24 billion in 2027 with a compound annual growth rate (CAGR) of 7% for the period of 2022-2027.
The contraceptive products as a segment of the global human reproductive technologies market is valued at $9.3 billion in 2021 and is estimated to grow from $10 billion in 2022 to $14.7 billion in 2027 with a CAGR of 7.8% for the period of 2022-2027.
The infertility pharmaceuticals products as a segment of the global human reproductive technologies market is valued at $2.5 billion in 2021 and is estimated to grow from $2.7 billion in 2022 to $3.9 billion in 2027 with a CAGR of 7.5% for the period of 2022-2027
The report is designed to be a comprehensive business tool to provide an in-depth look at the markets for reproductive drugs and technologies. The geographic scope of the report is global. The report reviews male and female reproductive health, presents standard pharmaceutical treatments and devices, and reviews technologies associated with reproductive health. The report also explores market size, identifies market participants, and investigates pipeline products and technologies.
The global market for reproductive technologies and products is divided into categories by treatment type and indication as follows.
Infertility market - male and female factors, pharmaceuticals, and future advancements.
Contraception - pharmaceuticals and devices.
Sexual dysfunction - pharmaceuticals and devices.
Each area is covered in detail, describing the disorder or treatment involved, identifying current products and treatments in the market in the base year 2021, measuring current market size and identifying current and potential market drivers, forecasting for 2027, assessing current and potential competitors, and identifying current competitor market shares for the base year of 2021.